First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401 Patients who underwent ...
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A ...
All patients underwent either L-PCLND (n = 46) or O-PCLND (n = 21) at the Charité University Medicine Berlin between October 1999 and March 2010. The Charité department of urology is performing ...
Luca Antonelli, MD; Davide Ardizzone, MD; Isamu Tachibana, MD; Nabil Adra, MD; Clint Cary, MD; Lee Hugar, MD; Wade J. Sexton, MD; Aditya Bagrodia, MD; Michal Mego, MD ...
Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limited ...
Colorectal cancer (CRC) remains one of the most prevalent malignancies worldwide, and its management becomes increasingly complex when para‐aortic lymph node metastasis (PALNM) is present. Although ...
On the basis of National Comprehensive Cancer Network guidelines, clinical stage (CS) II seminoma is treated with radiotherapy or chemotherapy. Primary retroperitoneal lymph node dissection (RPLND) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results